Epigenetic modulation of neuroblastoma enhances T cell and NK cell immunogenicity by inducing a tumor-cell lineage switch

BACKGROUND: Immunotherapy in high-risk neuroblastoma (HR-NBL) does not live up to its full potential due to inadequate (adaptive) immune engagement caused by the extensive immunomodulatory capacity of HR-NBL. We aimed to tackle one of the most notable immunomodulatory processes in neuroblastoma (NBL...

Descripción completa

Detalles Bibliográficos
Autores principales: Cornel, Annelisa M, Dunnebach, Ester, Hofman, Damon A, Das, Sanjukta, Sengupta, Satyaki, van den Ham, Femke, Wienke, Judith, Strijker, Josephine G M, van den Beemt, Denise A M H, Essing, Anke H W, Koopmans, Bianca, Engels, Sem A G, Lo Presti, Vania, Szanto, Celina S, George, Rani E, Molenaar, Jan J, van Heesch, Sebastiaan, Dierselhuis, Miranda P, Nierkens, S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Basic Tumor Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9756225/
https://www.ncbi.nlm.nih.gov/pubmed/36521927
http://dx.doi.org/10.1136/jitc-2022-005002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9756225/
https://www.ncbi.nlm.nih.gov/pubmed/36521927
http://dx.doi.org/10.1136/jitc-2022-005002

Ejemplares similares